Fusion protein having enhanced in vivo erythropoietin activity

Details Fusion protein having enhanced in vivo erythropoietin activity Fusion protein having enhanced in vivo erythropoietin activity

2006-08-15

2006-08-15

Brumback, Brenda (Department: 1647)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Glycoprotein, e.g., mucins, proteoglycans, etc.

C530S399000, C435S069100

Reexamination Certificate

active

07091326

ABSTRACT:
Provided is a fusion protein comprising, at its carboxy terminal of human erythropoietin (EPO), a mutant having one to four amino acid substitutions in the carboxy terminal peptide (CTP) fragment of a human chorionic gonadotropin (HCG) β subunit, for increasing an in vivo half-life activity of EPO. The in vivo half-life can be greatly elongated while retaining the intrinsic activity of the EPO, without increasing the sugar chain content.

REFERENCES:
patent: 5712122 (1998-01-01), Boime et al.
patent: 0 640 619 (1995-03-01), None
patent: 0640619 (1995-03-01), None
patent: 8-506023 (1996-07-01), None
patent: 11-155584 (1999-06-01), None
patent: 2001-064300 (2001-03-01), None
patent: WO 95/05465 (1995-02-01), None
patent: WO 01/03737 (2001-01-01), None
patent: WO 01/36489 (2001-05-01), None
patent: WO 01/36489 (2001-05-01), None
patent: WO 02/48194 (2002-06-01), None
patent: WO 02/48194 (2002-06-01), None
Wells, Additivity of Mutational Effects in Proteins. Biochemistry 29:8509-8517 (1990).
Furuhashi et al., “Fusing the Carboxy-Terminal Peptide of the Chorionic Gonadotropin (CG) β-Subunit to the Common α-Subunit: Retention of O-Linked Glycosylation and Enhancedin VivoBioactivity of Chimeric Human CG, Molecular Endocrinology”, 9:1, 54-63 (1995).
Sytkowski et al., “An Erythropoietin Fusion Protein Comprised of Identical Repeating Domains Exhibits Enhanced Biological Properties”, The Journal of Biological Chemistry, 274:35, 24773-24778, 1999.
Communication from Japanese Patent Office.

Affiliated with

Also associated with

Rating

Fusion protein having enhanced in vivo erythropoietin activity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Fusion protein having enhanced in vivo erythropoietin activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fusion protein having enhanced in vivo erythropoietin activity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3705194